On October 8, 2024 GlyTherix Ltd reported that it has signed a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine (Press release, Glytherix, OCT 8, 2024, View Source [SID1234647108]). This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix’s clinical trials, aimed at treating aggressive cancers through innovative antibody radiopharmaceuticals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GlyTherix’s approach utilizes Lu-177 combined with an antibody targeting Glypican-1, a protein prevalent in several aggressive cancers, allowing for localized radiation treatment while protecting healthy tissue. Clinical trials are set to kick off in Australia in early 2025, followed by U.S. trials in 2026.

Dr Brad Walsh, CEO of GlyTherix, emphasized the importance of this partnership in further strengthening their global supply network, ensuring high-quality isotopes are available for patients. Dr. Harald Hasselmann, CEO of Eckert & Ziegler, echoed this sentiment, expressing enthusiasm for supporting groundbreaking treatments.

Together, we’re paving the way for the future of cancer therapy!